Leukoreduction before red blood cell transfusion has no impact

J. Surg. Res. · Mar 2007

Leukoreduction before red blood cell transfusion has no impact on mortality in trauma patients.

Studies suggest that leukocytes in donated blood increase mortality and length of hospital stay (LOS) after transfusion. These studies included few trauma patients, however. Many institutions now mandate leukoreduction (LR) of transfusion products, which increases costs by approximately $30/unit. The purpose of this study was to examine the effect of LR on mortality and LOS in trauma patients. ⋯ In those transfused patients who survive 48 h post-injury, LR of blood transfusion products has no beneficial impact on patient survival or hospital LOS. The associated costs of universal LR are not justified.

read more… mark as read…
- Herb A Phelan, Jason L Sperry, and Randall S Friese.
- Department of Surgery, Division of Trauma/Critical Care, University of South Alabama Medical Center, Mobile, Alabama, USA. hphela@yahoo.com <hphela@yahoo.com>
- J. Surg. Res. 2007 Mar 1;138(1):32-6.
BackgroundStudies suggest that leukocytes in donated blood increase mortality and length of hospital stay (LOS) after transfusion. These studies included few trauma patients, however. Many institutions now mandate leukoreduction (LR) of transfusion products, which increases costs by approximately $30/unit. The purpose of this study was to examine the effect of LR on mortality and LOS in trauma patients.MethodsA retrospective before-and-after cohort study was conducted at a level one urban trauma center. LR of all transfusion products commenced in January 2002. All patients treated within the intervention period (March 2002 through January 2004) received LR products. Those transfused during March 2000 through January 2002 served as controls. The trauma registry was queried for patients >or=18 years who survived >or=2 days and received >or=2 units of blood. Mortality and LOS were determined for each group. Subset analysis was performed on patients receiving 2-6 transfusions and those receiving massive transfusion (>or=6 units). Mortality and LOS for control and intervention subsets were compared. Means were compared using Student's t-test, proportions using chi(2) (significance P ResultsThere were 439 patients in the control group and 240 patients in the intervention group. Groups were similar in age and mechanism of injury. There was no difference in mortality overall (P = 0.68) or after massive transfusion (P = 0.14). There was no difference in LOS overall (control, 12 +/- 17 days; intervention, 12 +/- 13.8 days, P = 0.46) or after subset analysis.ConclusionsIn those transfused patients who survive 48 h post-injury, LR of blood transfusion products has no beneficial impact on patient survival or hospital LOS. The associated costs of universal LR are not justified.

Pubmed Full text Copy Citation Plaintext

Add institutional full text...
Notes
Knowledge, pearl, summary or comment to share?

300 characters remaining

help

You can also include formatting, links, images and footnotes in your notes

Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.

Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.

Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.

Links can be included with: [my link to pubmed](http://pubmed.com)

Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")

For footnotes use [^1](This is a footnote.) inline.

Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..
hide…

Leukoreduction before red blood cell transfusion has no impact on mortality in trauma patients.

Notes

300 characters remaining

help

You can also include formatting, links, images and footnotes in your notes

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.